Organization | Institut Hospitalier Franco-Britannique

Institut Hospitalier Franco-Britannique Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2013

NCT01910610

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Franco-British Hospital - GCS IHFB Cognacq-Jay | Franco-British Hospital GCS IHFB Cognacq-Jay | GCS IHFB Cognacq-Jay

Active Ingredients

Drugs in Phase 3 Trials (9)

aflibercept (zaltrap) (1 trial)

bevacizumab (avastin) (1 trial)

capecitabine (xeloda) (1 trial)

cetuximab (erbitux) (2 trials)

fluorouracil (efudex) (2 trials)

irinotecan (Camptosar) (3 trials)

leucovorin (2 trials)

oxaliplatin (eloxatin) (1 trial)

panitumumab (vectibix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Colorectal Neoplasms (Phase 3)

Neoplasm Metastasis (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 9